Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators.
Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16.
Ovarian remnant syndrome.
Magtibay PM, Magrina JF.
Clin Obstet Gynecol. 2006 Sep;49(3):526-34. doi: 10.1097/00003081-200609000-00012.
Ovarian remnant syndrome.
Webb MJ.
Aust N Z J Obstet Gynaecol. 1989 Nov;29(4):433-5. doi: 10.1111/j.1479-828x.1989.tb01783.x.
The VCD Mouse Model of Menopause and Perimenopause for the Study of Sex Differences in Cardiovascular Disease and the Metabolic Syndrome.
Brooks HL, Pollow DP, Hoyer PB.
Physiology (Bethesda). 2016 Jul;31(4):250-7. doi: 10.1152/physiol.00057.2014.
Ovarian remnant syndrome.
Magtibay PM, Nyholm JL, Hernandez JL, Podratz KC.
Am J Obstet Gynecol. 2005 Dec;193(6):2062-6. doi: 10.1016/j.ajog.2005.07.067.
Ovarian residual syndrome.
Bukovsky I, Liftshitz Y, Langer R, Weinraub Z, Sadovsky G, Caspi E.
Surg Gynecol Obstet. 1988 Aug;167(2):132-4.
Residual ovarian syndrome: A case report with classic symptoms, imaging and pathology findings, and treatment.
Fu SC, Su HY.
Taiwan J Obstet Gynecol. 2018 Oct;57(5):753-754. doi: 10.1016/j.tjog.2018.08.027.
Ovarian remnant syndrome: an unsuspected diagnosis.
Colombi I, Centini G, Martire FG, Ginetti A, Cannoni A, Lazzeri L, Severi FM, Zupi E.
Facts Views Vis Obgyn. 2025 Jun 27;17(2):170-179. doi: 10.52054/FVVO.2025.49. Epub 2025 Jun 10.
Gonadotropinomas.
Chaidarun SS, Klibanski A.
Semin Reprod Med. 2002 Nov;20(4):339-48. doi: 10.1055/s-2002-36708.
Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine.
Heddar A, Ogur C, Da Costa S, Braham I, Billaud-Rist L, Findikli N, Beneteau C, Reynaud R, Mahmoud K, Legrand S, Marchand M, Cedrin-Durnerin I, Cantalloube A, Peigne M, Bretault M, Dagher-Hayeck B, Perol S, Droumaguet C, Cavkaytar S, Nicolas-Bonne C, Elloumi H, Khrouf M, Rougier-LeMasle C, Fradin M, Le Boette E, Luigi P, Guerrot AM, Ginglinger E, Zampa A, Fauconnier A, Auger N, Paris F, Brischoux-Boucher E, Cabrol C, Brun A, Guyon L, Berard M, Riviere A, Gruchy N, Odent S, Gilbert-Dussardier B, Isidor B, Piard J, Lambert L, Hamamah S, Guedj AM, Brac de la Perriere A, Fernandez H, Raffin-Sanson ML, Polak M, Letur H, Epelboin S, Plu-Bureau G, Wołczyński S, Hieronimus S, Aittomaki K, Catteau-Jonard S, Misrahi M.
EBioMedicine. 2022 Oct;84:104246. doi: 10.1016/j.ebiom.2022.104246. Epub 2022 Sep 10.
